What is Novo Integrated Sciences Return-on-Tangible-Equity?
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Novo Integrated Sciences's annualized net income for the quarter that ended in Feb. 2024 was $-10.98 Mil. Novo Integrated Sciences's average shareholder tangible equity for the quarter that ended in Feb. 2024 was $-0.13 Mil. Therefore, Novo Integrated Sciences's annualized Return-on-Tangible-Equity for the quarter that ended in Feb. 2024 was N/A%.
The historical rank and industry rank for Novo Integrated Sciences's Return-on-Tangible-Equity or its related term are showing as below:
NVOS'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -1078.65 Med: -193.83 Max: -35.65
Current: -1078.65
During the past 13 years, Novo Integrated Sciences's highest Return-on-Tangible-Equity was -35.65%. The lowest was -1,078.65%. And the median was -193.83%.
NVOS's Return-on-Tangible-Equity is ranked worse than 98.89% of 540
companies
in the Healthcare Providers & Services industry
Industry Median: 10.255
vs NVOS: -1078.65
Novo Integrated Sciences Return-on-Tangible-Equity Historical Data
The historical data trend for Novo Integrated Sciences's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Novo Integrated Sciences Return-on-Tangible-Equity Chart
Competitive Comparison of Novo Integrated Sciences's Return-on-Tangible-Equity
For the Medical Care Facilities subindustry, Novo Integrated Sciences's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novo Integrated Sciences's Return-on-Tangible-Equity Distribution in the Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Novo Integrated Sciences's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Novo Integrated Sciences's Return-on-Tangible-Equity falls into.
Novo Integrated Sciences Return-on-Tangible-Equity Calculation
Novo Integrated Sciences's annualized Return-on-Tangible-Equity for the fiscal year that ended in Aug. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Feb. 2024) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
Novo Integrated Sciences (NAS:NVOS) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Novo Integrated Sciences Return-on-Tangible-Equity Related Terms
Thank you for viewing the detailed overview of Novo Integrated Sciences's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Novo Integrated Sciences (Novo Integrated Sciences) Business Description
Novo Integrated Sciences Inc is a medical care company. It provides specialized physiotherapy, chiropractic care, occupational therapy, eldercare, laser therapeutics, massage therapy, acupuncture, neurological functions, kinesiology, and others. It has two reportable segments: healthcare services which generates majority of the revenue, and product sales.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NVOS has been successfully added to your 